LifeArc
17
27M
13
0.53
3
0.24
1
- Areas of investment
Summary
LifeArc appeared to be the Corporate Investor, which was created in 1992. The main department of described Corporate Investor is located in the London. The fund was located in Europe if to be more exact in United Kingdom.
Considering the real fund results, this Corporate Investor is 30 percentage points more often commits exit comparing to other organizations. The fund is generally included in less than 2 deals every year. Opposing the other organizations, this LifeArc works on 4 percentage points less the average amount of lead investments. The important activity for fund was in 2019. The usual things for fund are deals in the range of 50 - 100 millions dollars.
Among the most successful fund investment fields, there are Biopharma, Therapeutics. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline AMR Centre, Caldan Therapeutics For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the LifeArc, startups are often financed by Scottish Investment Bank, Scottish Enterprise, Science Ventures. The meaningful sponsors for the fund in investment in the same round are Pfizer Venture Investments, OrbiMed, SciTech. In the next rounds fund is usually obtained by Samsara BioCapital, Pfizer Venture Investments, Perceptive Advisors.
Investments analytics
Analytics
- Total investments
- 17
- Lead investments
- 3
- Exits
- 1
- Rounds per year
- 0.53
- Follow on index
- 0.24
- Investments by industry
- Biotechnology (11)
- Health Care (8)
- Therapeutics (6)
- Pharmaceutical (6)
- Biopharma (3) Show 8 more
- Investments by region
- United States (3)
- United Kingdom (13)
- Sweden (1)
- Peak activity year
- 2020
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Avg. valuation at time of investment
- 885K
- Group Appearance index
- 0.82
- Avg. company exit year
- 3
- Strategy success index
- 0.30
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| DJS Antibodies | 22 Dec 2020 | Biotechnology, Health Care | Seed | 8M | England, Oxford, United Kingdom |
| Grexter | 11 Jan 2019 | Real Estate | Seed | 1M | Karnataka, India, Bengaluru |
| Ordr | 26 Feb 2019 | Internet, Software, Artificial Intelligence, Machine Learning, Cyber Security, Network Security, Cloud Computing, Internet of Things | Early Stage Venture | 16M | United States, California, San Jose |
| SpringWorks Therapeutics | 01 Apr 2019 | Biotechnology, Therapeutics, Biopharma | Early Stage Venture | 125M | United States, Connecticut, Stamford |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.